Teva Pharmaceutical Industries (NYSE:TEVA) Coverage Initiated by Analysts at Morgan Stanley

Morgan Stanley began coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) in a research note issued to investors on Thursday, The Fly reports. The brokerage issued an equal weight rating and a $10.00 price target on the stock.

A number of other brokerages also recently issued reports on TEVA. StockNews.com initiated coverage on Teva Pharmaceutical Industries in a report on Thursday, May 18th. They issued a buy rating for the company. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $13.00 to $14.00 and gave the company an overweight rating in a research report on Thursday, February 9th. Finally, Evercore ISI raised shares of Teva Pharmaceutical Industries from an in-line rating to an outperform rating in a research report on Thursday, May 18th. Three analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of Hold and an average target price of $10.67.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $7.33 on Thursday. Teva Pharmaceutical Industries has a 12-month low of $6.78 and a 12-month high of $11.44. The company has a current ratio of 1.10, a quick ratio of 0.71 and a debt-to-equity ratio of 2.28. The stock has a fifty day moving average price of $8.60 and a 200 day moving average price of $9.27.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last announced its quarterly earnings data on Wednesday, May 10th. The company reported $0.37 EPS for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.18). The firm had revenue of $3.66 billion during the quarter, compared to analysts’ expectations of $3.60 billion. Teva Pharmaceutical Industries had a negative net margin of 10.73% and a positive return on equity of 27.58%. Equities analysts expect that Teva Pharmaceutical Industries will post 2.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, VP David Matthew Stark sold 63,383 shares of the company’s stock in a transaction on Tuesday, February 28th. The shares were sold at an average price of $9.89, for a total transaction of $626,857.87. Following the completion of the transaction, the vice president now owns 2,974 shares in the company, valued at approximately $29,412.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, VP David Matthew Stark sold 63,383 shares of the stock in a transaction that occurred on Tuesday, February 28th. The stock was sold at an average price of $9.89, for a total transaction of $626,857.87. Following the completion of the transaction, the vice president now directly owns 2,974 shares of the company’s stock, valued at approximately $29,412.86. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Sven Dethlefs sold 19,355 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $9.93, for a total value of $192,195.15. Following the completion of the sale, the executive vice president now owns 223,447 shares in the company, valued at $2,218,828.71. The disclosure for this sale can be found here. Insiders sold a total of 158,884 shares of company stock valued at $1,572,797 over the last three months. 0.82% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of large investors have recently made changes to their positions in the stock. Advanced Portfolio Management LLC acquired a new position in Teva Pharmaceutical Industries during the first quarter worth about $2,655,000. Mercer Global Advisors Inc. ADV boosted its stake in shares of Teva Pharmaceutical Industries by 0.9% during the 1st quarter. Mercer Global Advisors Inc. ADV now owns 182,957 shares of the company’s stock worth $1,619,000 after acquiring an additional 1,622 shares in the last quarter. Quilter Plc acquired a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter worth approximately $3,103,125,000. Apollon Wealth Management LLC increased its stake in Teva Pharmaceutical Industries by 28.3% in the 1st quarter. Apollon Wealth Management LLC now owns 30,313 shares of the company’s stock valued at $268,000 after purchasing an additional 6,685 shares in the last quarter. Finally, State Street Corp raised its holdings in Teva Pharmaceutical Industries by 29.4% during the first quarter. State Street Corp now owns 19,564,828 shares of the company’s stock worth $172,988,000 after purchasing an additional 4,441,883 shares during the last quarter. Hedge funds and other institutional investors own 50.39% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

(Get Rating)

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.